| Autor: |
von Eyben FE; Center of Tobacco Control Research, DK-5230 Odense, Denmark., Kairemo K; Department of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, FI-00185 Helsinki, Finland., Kapp DS; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Biomedicines [Biomedicines] 2024 Apr 08; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 08. |
| DOI: |
10.3390/biomedicines12040822 |
| Abstrakt: |
Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa. The SR was registered as InPLASY2023110084. We searched for studies on Google Scholar, PUBMED and reference lists of reviews and studies. We only included studies on uPSAs published in English and excluded studies of women, animals, sarcoidosis and reviews. Of the 115 included studies, 39 reported PSA assay methods and 76 reported clinical findings. Of 67,479 patients, 14,965 developed PSA recurrence (PSAR) and 2663 died. Extremely low PSA nadir and early developments of PSA separated PSAR-prone from non-PSAR-prone patients (cumulative p value 3.7 × 10 12 ). RP patients with the lowest post-surgery PSA nadir and patients who had the lowest PSA at SRT had the fewest deaths. In conclusion, PSA for patients with localized PCa in the pre-PSAR phase of PCa is strongly associated with later PSAR and survival. A rising but still exceedingly low PSA at SRT predicts a good 5-year overall survival. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
